CINC280J12201

Status: Active Trial | Marker: MET Title A double-blind, Placebo controlled, randomized, Phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and Placebo as first line Treatment for...